New GAO Report: 1 November 2007:
Preliminary findings suggest weaknesses in the FDA’s program for inspecting foreign drug manufacturers . This report, which includes testimony before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives, discusses preliminary information on (1) the extent to which the FDA has accurate data to manage the foreign drug inspection program, (2) the frequency of foreign inspections and factors influencing the selection of establishments to inspect, and (3) issues unique to conducting foreign inspections.
Source: Government Accountability Office
